NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OCGN

Ocugen Inc

Jul 02 • 10:13AM ET

0.9296

Dollar change +0.0055
Percentage change 0.60	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX INO VXRT SAGE MCRB ADMA VTVT

| Held by: VTI VXF VTWO VHT IWM MOON IWO VTWG IWC QQQS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.19	Insider Own	1.80%	Shs Outstand	292.03M	Perf Week	-10.62%
Market Cap	271.48M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	286.77M	Perf Month	11.04%
Enterprise Value	265.50M	PEG	-	EPS next Q	-0.06	Inst Own	26.40%	Short Float	22.73%	Perf Quarter	43.63%
Income	-52.49M	P/S	60.06	EPS this Y	-10.00%	Inst Trans	6.97%	Short Ratio	11.62	Perf Half Y	9.93%
Sales	4.52M	P/B	17.06	EPS next Y	-9.09%	ROA	-98.89%	Short Interest	65.19M	Perf YTD	15.48%
Book/sh	0.05	P/C	7.18	EPS next 5Y	-	ROE	-248.97%	52W High	1.98 -53.03%	Perf Year	-40.03%
Cash/sh	0.13	P/FCF	-	EPS past 3/5Y	12.68% 32.82%	ROIC	-111.69%	52W Low	0.51 80.50%	Perf 3Y	-61.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	40.34%	Volatility	7.78% 9.43%	Perf 5Y	295.24%
Dividend TTM	-	EV/Sales	58.74	EPS Y/Y TTM	22.29%	Oper. Margin	-1261.43%	ATR (14)	0.09	Perf 10Y	-99.77%
Dividend Ex-Date	-	Quick Ratio	2.60	Sales Y/Y TTM	86.63%	Profit Margin	-1160.86%	RSI (14)	44.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.60	EPS Q/Q	-13.36%	SMA20	-11.06%	Beta	3.87	Target Price	6.50
Payout	-	Debt/Eq	2.00	Sales Q/Q	46.06%	SMA50	5.71%	Rel Volume	0.71	Prev Close	0.92
Employees	95	LT Debt/Eq	1.95	Earnings	May 09 BMO	SMA200	11.82%	Avg Volume	5.61M	Price	0.93
IPO	Dec 03, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.04% -	Trades		Volume	614,709	Change	0.60%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-24	Initiated	Maxim Group	Buy	$4
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$3.50
Aug-23-22	Initiated	Mizuho	Buy	$5
Jun-15-22	Resumed	ROTH Capital	Buy	$8
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral	$10 → $6
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$0.70 → $13
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$4.50

Jun-24-25 01:07PM	Carisma Therapeutics, OrthoCellix enter definitive merger agreement (TipRanks) +5.49%
Jun-23-25 07:30AM	Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire) -7.44%
Jun-17-25 07:49AM	FDA clears Ocugens IND amendment for trial of Stargardt disease treatment (Clinical Trials Arena) -6.03%
Jun-16-25 07:02AM	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire)
Jun-11-25 07:30AM	Ocugen To Present at BIO International Convention 2025 (GlobeNewswire)
07:02AM	Loading…
Jun-05-25 07:02AM	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire) +7.41%
May-27-25 07:02AM	Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease (GlobeNewswire)
May-10-25 03:04AM	Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... (GuruFocus.com)
May-09-25 08:07AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
08:01AM	Ocugen Provides Business Update with First Quarter 2025 Financial Results (GlobeNewswire)
May-02-25 08:00AM	Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 07:30AM	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress (GlobeNewswire)
Apr-16-25 10:01AM	Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? (Insider Monkey) -6.53%
Apr-08-25 08:02AM	Ocugen to Present at the 2025 Cell & Gene Meeting on the Med (GlobeNewswire) -10.17%
Mar-26-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
06:18AM	Loading…
Mar-19-25 06:18AM	Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 (Clinical Trials Arena) +6.31%
Mar-18-25 08:02AM	Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200 a Novel Fusion Protein for Diabetic Macular Edema (GlobeNewswire) -9.83%
Mar-06-25 02:07AM	Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com) +9.96%
Mar-05-25 11:48PM	Q4 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
01:15PM	Ocugen (OCGN) Q4 2024 Earnings Call Transcript (Motley Fool)
07:21AM	Ocugen: Q4 Earnings Snapshot (Associated Press Finance)
07:02AM	Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 09:00AM	Ocugen Announces Positive Opinion of EMAs Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease (GlobeNewswire) -7.15%
08:26AM	Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) (GlobeNewswire)
Feb-27-25 08:46AM	Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease (GlobeNewswire)
Feb-24-25 05:14PM	Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) (GlobeNewswire) -7.35%
Feb-21-25 08:00AM	Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 05:41PM	Why Ocugen (OCGN) Is Advancing Today (Insider Monkey) +6.47%
Feb-12-25 07:42AM	Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410-a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Feb-03-25 06:30AM	Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa (GlobeNewswire)
06:30AM	Loading…
Jan-27-25 06:30AM	Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 (GlobeNewswire) -6.27%
Jan-17-25 05:31AM	Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment (Clinical Trials Arena)
Jan-16-25 07:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200 a Novel Integrin-Targeting Biologic for Diabetic Macular Edema (GlobeNewswire)
Jan-13-25 06:30AM	Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 A Novel Modifier Gene Therapy for Retinitis Pigmentosa (GlobeNewswire)
Dec-19-24 06:38AM	Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Dec-11-24 07:02AM	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire)
Nov-27-24 07:09AM	Ocugen CEO to Present at NobleCon20 Noble Capital Markets' 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +6.74%
Nov-20-24 07:30AM	Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease (GlobeNewswire) +5.14%
Nov-19-24 07:02AM	Ocugen Announces Compelling Preliminary Data for OCU410 a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Nov-14-24 04:40PM	Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.14%
03:32PM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
Nov-09-24 02:14AM	Q3 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-08-24 11:15AM	Ocugen (OCGN) Q3 2024 Earnings Call Transcript (Motley Fool) -8.69%
06:45AM	Ocugen Provides Business Update with Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 06:30AM	Ocugen Secures $30 Million in Debt Funding (GlobeNewswire) +8.88%
Oct-28-24 06:30AM	Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 (GlobeNewswire) +9.24%
Oct-22-24 07:02AM	Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease (GlobeNewswire)
Oct-17-24 07:30AM	Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition of Shares in Ocugen Inc (GuruFocus.com)
Oct-10-24 07:00AM	Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 05:35PM	Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
06:30AM	Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial (GlobeNewswire)
Oct-02-24 06:30AM	Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-24-24 07:30AM	Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.13%
Sep-09-24 06:30AM	Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop (GlobeNewswire) +9.65%
Sep-05-24 07:00AM	Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit (GlobeNewswire)
Sep-03-24 07:30AM	Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.92%
Aug-28-24 06:30AM	Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
Aug-26-24 07:02AM	Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Aug-08-24 10:49PM	Q2 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) +8.47%
05:30PM	Ocugen (OCGN) Q2 2024 Earnings Call Transcript (Motley Fool)
06:45AM	Ocugen Provides Business Update with Second Quarter 2024 Financial Results (GlobeNewswire)
06:27AM	Ocugen: Q2 Earnings Snapshot (Associated Press Finance)
Aug-05-24 06:30AM	Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa (GlobeNewswire)
Aug-02-24 03:22PM	Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock (GlobeNewswire) -5.77%
Jul-31-24 09:15PM	Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock (GlobeNewswire) -7.47%
04:15PM	Ocugen, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jul-29-24 07:02AM	Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire) -9.76%
Jul-25-24 06:30AM	Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Novel Modifier Gene Therapy (GlobeNewswire)
Jul-11-24 08:45AM	1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid (Motley Fool)
Jul-06-24 06:39AM	3 Penny Stocks That Could Turn $10K Into $100K in 3 Years (InvestorPlace)
Jun-24-24 09:40AM	Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.26%
06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-21-24 07:00AM	Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease (GlobeNewswire)
Jun-20-24 08:23AM	3 Penny Stocks Set to Make New Millionaires in 2024 (InvestorPlace) -6.88%
06:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400 First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.58%
Jun-05-24 09:25AM	Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why (Zacks)
May-31-24 08:36AM	Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy (GlobeNewswire) +8.81%
May-29-24 07:15AM	Ocugen to Present at BIO International Convention 2024 (GlobeNewswire)
May-28-24 07:02AM	Ocugen Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
May-24-24 08:10AM	1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole (Motley Fool)
May-20-24 07:00AM	Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 (GlobeNewswire)
May-15-24 07:30AM	Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study (MT Newswires) +15.29%
06:30AM	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
03:02AM	Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:12AM	Q1 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 11:53AM	OCGN Stock Earnings: Ocugen Beats EPS for Q1 2024 (InvestorPlace) -6.08%
08:00AM	Ocugen Provides Business Update with First Quarter 2024 Financial Results (GlobeNewswire)
06:43AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
May-10-24 04:05PM	Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock (GlobeNewswire) +13.84%
07:45AM	Ocugen to Present at May 2024 Investor Conferences (GlobeNewswire)
May-08-24 06:00AM	Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028 (InvestorPlace) +9.55%
May-03-24 07:30AM	Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 07:15AM	Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress (GlobeNewswire) -5.04%
Apr-29-24 08:30AM	Can Ocugen Stock Keep Churning Higher? (Motley Fool) +8.59%
06:45AM	Ocugen Announces OCU400 Modifier Gene Therapy Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 (GlobeNewswire)
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-26-24 12:35PM	Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? (Zacks) +8.47%

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PRABHAVATHI FERNANDES	Director	Jun 11 '25	Proposed Sale	1.17	146,705	171,029		Jun 11 05:46 PM
Fernandes Prabhavathi	Director	Nov 26 '24	Buy	0.91	10,000	9,095	10,000	Dec 02 04:15 PM
Castillo Kirsten	Director	Nov 22 '24	Buy	0.91	25,000	22,848	75,000	Nov 26 04:50 PM
RAMESH KUMAR	Director	Aug 16 '24	Proposed Sale	1.25	116,705	145,905		Aug 16 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCGN

Ocugen Inc

Upgrade your FINVIZ experience